Navigation Links
Medivir Announces Positive Data From the Phase II Study of Remetinostat in Patients With Early-stage Cutaneous T-cell Lymphoma
Date:4/7/2017

STOCKHOLM, April 7, 2016 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces the completion of the phase II clinical study of the topical, skin-directed histone deacetylase (HDAC) inhibitor, remetinostat, in patients with early stage CTCL. The trial included 60 patients with the mycosis fungoides (MF) variant of CTCL, who were randomized to receive either 0.5% remetinostat gel BID, 1% remetinostat gel QD or 1% remetinostat gel BID for between 6 and 12 months. The primary end-point of the study was the proportion of patients with either a complete or partial confirmed response to therapy, assessed using the Composite Assessment of Index Lesion Severity (CAILS). Based on an intent-to-treat analysis, patients in the 1% remetinostat gel BID arm had highest proportion of confirmed responses (8/20, 40%), including 1 complete response. The response rates in the other two arms were 5/20 (25%) and 4/20 (20%) in the 0.5% BID arm and the 1% QD arm respectively, and did not include any complete responses. Across all the dose groups, remetinostat was well-tolerated without signs of systemic adverse effects, including those associated with systemic HDAC inhibitors.

Based on these data, Medivir expects to initiate discussions with regulatory authorities with the aim of initiating a phase III study later this year, and to present full phase II trial data at scientific meetings in the second half of 2017.

CTCL is a chronic, orphan hematologic cancer that presents in the skin. According to the National Cancer Institute, the most common CTCL is the mycosis fungoides (MF) variant of CTCL. MF affects an estimated 15,000 to 20,000 people in the United States, with an estimated 1,500 new cases annually, and around 75% of these have early-stage disease. Patients remain at this stage for extended periods and require long-term topical treatments for their disease, which causes substantial reductions in patients' quality of life. A small proportion of patients go on to develop cutaneous tumors or systemic disease, and these patients then require systemic anti-cancer therapy. Medivir estimates that the addressable market for early-stage CTCL in the US alone is approximately USD 900m annually.

"The results of this study confirm and extend the previously published interim analysis of the phase II study, and show that remetinostat has the potential to be a safe and effective new treatment for patients with early-stage CTCL" said Dr Richard Bethell, Medivir's Chief Scientific Officer. "There are few drugs available for the treatment of the disease, and those currently available have generally poor tolerability. As a result, CTCL patients and their physicians require safe and effective new treatment options. Remetinostat was designed to effectively inhibit HDACs within cutaneous lesions, but to be rapidly broken down in the bloodstream, preventing the side effects associated with systemically administered HDAC inhibitors. Based on the efficacy and safety data from this Phase II study, we believe that remetinostat is capable of meeting a very important unmet need in patients with this chronic and poorly treated orphan disease."

For further information, please contact:
Ola Burmark
CFO Medivir AB
Mobile: +46 (0) 725-480-580

Richard Bethell
CSO Medivir AB
Mobile +46 (0) 72-704-3211

This information is information that Medivir AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 08.30 CET on 7 April 2017.

About Medivir
Medivir is a research-based pharmaceutical company with a focus on oncology. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical needs. Medivir is listed on the Nasdaq Stockholm Mid Cap List.

This information was brought to you by Cision http://news.cision.com
http://news.cision.com/medivir/r/medivir-announces-positive-data-from-the-phase-ii-study-of-remetinostat-in-patients-with-early-stage,c2234530

The following files are available for download:

http://mb.cision.com/Main/652/2234530/654619.pdf

Press release (PDF)

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/medivir-announces-positive-data-from-the-phase-ii-study-of-remetinostat-in-patients-with-early-stage-cutaneous-t-cell-lymphoma-300436504.html


'/>"/>
SOURCE Medivir
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Number of Shares and Votes in Medivir
2. Medivir Completes Transition of Commercial Products to Fully Focus on Research and Development
3. Presentation of the Result of Medivirs Voluntary Redemption Programme
4. Medivirs Nomination Committee Proposes new Board of Directors Ahead of 2017 AGM
5. Christine Lind new CEO of Medivir AB Effective 1 April 2017
6. Medivir - Invitation to Conference Call and Webcast
7. Medivir Completes Previously Announced Oncology Programs Acquisition
8. Current Hepatitis C Virus Regimens to Face Stiff Competition with the Launch of Gileads Sofosbuvir and Janssen/Medivirs Simeprevir
9. Terumo Cardiovascular Group Announces New President and CEO, Robert DeRyke
10. Regeneron Announces Evinacumab has Received FDA Breakthrough Therapy Designation for Homozygous Familial Hypercholesterolemia (HoFH)
11. Aralez Announces Reduction In U.S. Sales Force And Cost Savings Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2017)... , June 19, 2017  Researchers from DRUGSCAN ® ... they will host a live, complimentary webinar titled, "Untangling ... benchtop to the real world" on Wednesday June 28, ... This webinar will feature interviews with recreational ... into the manipulation techniques abusers use to prepare opioid ...
(Date:6/14/2017)... , June 14, 2017  ivWatch LLC, a ... effectiveness of intravenous (IV) therapy, is pleased to announce ... category of Nonsurgical Hospital Supplies and Equipment at the ... program for the medtech industry. The award was presented ... Jacob K. Javits Center in New York ...
(Date:6/13/2017)... , June 13, 2017 Zimmer Biomet Holdings, Inc. ... today announced that the U.S. Food and Drug Administration (FDA) ... 3, 2015 relating to its Zhejiang, China ... "The successful clearance of the Warning Letter ... manufacturing facility is a measure of the progress we have ...
Breaking Medicine Technology:
(Date:6/23/2017)... ... June 23, 2017 , ... The Rhode Island Quality ... Management Alerts and Dashboards, an innovative new service enabling healthcare providers to proactively ... Management Alerts and Dashboards provide near real-time data about patients admitted to and/or ...
(Date:6/23/2017)... ... ... By scoring 100% for fiscal management and accountability, the Arthritis National Research ... Charity Navigator, validating ANRF's work as a top charity in America. , This achievement ... earns ANRF a spot on their “ 10 Charities Worth Watching ” list as ...
(Date:6/23/2017)... ... ... Studies show evidence that carotenoids and antioxidants derived either from the diet or from ... how often do ophthalmologists and optometrists in Sweden recommend the use of nutritional supplements, ... symptoms of AMD? A study published recently in Dove Medical Press journal, ...
(Date:6/23/2017)... ... June 23, 2017 , ... Dr. Ran Y. ... has recently begun offering three new minimally invasive procedures to patients who want ... reducing downtime, Dr. Rubinstein is excited to bring microneedling, microneedling facials, and platelet ...
(Date:6/23/2017)... ... 2017 , ... Everybody has their own personal preference when it comes to ... some people don't like it at all. FindaTopDoc took a look at what makes ... can give readers a taste of their deepest, darkest fantasies and has the ability ...
Breaking Medicine News(10 mins):